Status:
COMPLETED
Effect of Intrathecal Neostigmine on Post-dural Puncture Headache.
Lead Sponsor:
Alexandria University
Collaborating Sponsors:
Kasr El Aini Hospital
Fayoum University
Conditions:
Post-Dural Puncture Headache
Eligibility:
FEMALE
20-40 years
Phase:
PHASE4
Brief Summary
Intravenous neostigmine was recently reported as an effective treatment for PDPH for parturients after intrathecal (IT) block which is postulated to be through its central effects on CSF secretion and...
Detailed Description
Upon arrival to the operating room standard monitors will be applied and continued all over the operation, an 18G peripheral intravenous (IV) cannula will be inserted, and 15 ml/kg of Ringer lactate s...
Eligibility Criteria
Inclusion
- American society association (ASA) physical status class II parturients with a single fetus who will be scheduled for an elective caesarian section by Intrathecal block.
Exclusion
- Body mass index more than or equal to 35 kg/m2.
- Any contraindication to Intrathecal blocks such as local infection, bleeding disorders, or parturient refusal.
- Allergy to neostigmine or other drugs will be used in the study.
- Long-term opioid use.
- A history of chronic pain, migraine, cluster headache.
- Digestive problems with nausea and vomiting; cognitive dysfunction or memory disorders.
- Significant renal, hepatic, and cardiovascular diseases.
- History of urinary retention or bronchial asthma.
- Inadequate or failed Intrathecal block.
- Complicated pregnancy such as hypertensive disorders of the pregnancy, abnormal placenta, or uterine atony.
Key Trial Info
Start Date :
April 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 25 2023
Estimated Enrollment :
722 Patients enrolled
Trial Details
Trial ID
NCT05289323
Start Date
April 25 2022
End Date
July 25 2023
Last Update
July 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alexandria University
Alexandria, Egypt